Edwards Lifesciences Corp Cash & Equivalents 2007-2025 | EW
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is Edwards Lifesciences Corp's current cash & equivalents?
Edwards Lifesciences Corp (EW) annual cash & equivalents for 2024 was $3.05B, a 168.94% increase from 2023. Edwards Lifesciences Corp cash & equivalents for the quarter ending September 30, 2025 was $2.69B.
What was Edwards Lifesciences Corp's cash & equivalents in 2023?
Edwards Lifesciences Corp annual cash & equivalents for 2023 was $1.13B, a 47.24% increase from 2022.
What was Edwards Lifesciences Corp's cash & equivalents in 2022?
Edwards Lifesciences Corp annual cash & equivalents for 2022 was $769.0M, a 10.87% decline from 2021.
What is Edwards Lifesciences Corp's 5-year cash & equivalents CAGR?
Edwards Lifesciences Corp cash & equivalents grew at a compound annual growth rate (CAGR) of 20.90% from FY2019 to FY2024, going from $1.18B to $3.05B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2024 | $3.05B | +168.9% | 10-K |
| FY2023 | $1.13B | +47.2% | 10-K |
| FY2022 | $769.0M | -10.9% | 10-K |
| FY2021 | $862.8M | -27.1% | 10-K |
| FY2020 | $1.18B | +0.3% | 10-K |
| FY2019 | $1.18B | +65.1% | 10-K |
| FY2018 | $714.1M | -12.7% | 10-K |
| FY2017 | $818.3M | -12.0% | 10-K |
| FY2016 | $930.1M | +29.5% | 10-K |
| FY2015 | $718.4M | +9.9% | 10-K |
| FY2014 | $653.8M | +55.5% | 10-K |
| FY2013 | $420.4M | +35.2% | 10-K |
| FY2012 | $310.9M | +81.6% | 10-K |
| FY2011 | $171.2M | -56.8% | 10-K |
| FY2010 | $396.1M | +18.6% | 10-K |
| FY2009 | $334.1M | +52.8% | 10-K |
| FY2008 | $218.7M | +54.2% | 10-K |
| FY2007 | $141.8M | - | 10-K |